CTIS2022-501918-55-00进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-552 in Participants with Mild Alzheimer's Disease. - M23-515
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participants between 50 and 90 years of age, inclusive, with a diagnosis of probable Alzheimer's disease according to the National Institute of Aging-Alzheimer's Association (NIA-AA) (2011) criteria., Mini-Mental State Examination (MMSE) score of 20 to 26, a Clinical Dementia Rating (CDR) global score of 0.5 or 1.0, with a CDR memory score of 0.5 or higher, and at least 1 CDR functional domain (community affairs, home and hobbies, or personal care) score of 0.5 or higher at Screening Visit 1.
排除标准
- •Clinically significant and/or unstable medical conditions or any other reason that the investigator determines would interfere with participation in this study (e.g., unlikely to adhere to the study or procedures, keep appointments, or is planning to relocate during the study) or would make the participant an unsuitable candidate to receive ABBV-552.
研究者
相似试验
进行中（未招募）
1 期
RIST4721 in Subjects with Palmoplantar PustulosisEUCTR2021-003029-31-HUAristea Therapeutics Inc.156
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)Cognitive Deficits in SchizophreniaMedDRA version: 17.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2012-000418-13-GBAbbVie Deutschland GmbH & Co. KG430
进行中（未招募）
1 期
RIST4721 in Subjects with Palmoplantar PustulosisPalmoplantar Pustulosis (PPP)MedDRA version: 21.1Level: PTClassification code 10050185Term: Palmoplantar pustulosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-003029-31-DEAristea Therapeutics Inc.156
进行中（未招募）
1 期
A controlled study to evaluate the safety and the effectiveness of different doses and dosing regimens of ISIS 681257 for the reduction of plasma Lp(a) levels in patients with hyperlipoproteinemia(a) and established Cardio Vascular Disease.EUCTR2016-003373-18-DKAkcea Therapeutics, Inc.270
进行中（未招募）
1 期
A controlled study to evaluate the safety and the effectiveness of different doses and dosing regimens of ISIS 681257 for the reduction of plasma Lp(a) levels in patients with hyperlipoproteinemia(a) and established Cardio Vascular Disease.Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)MedDRA version: 19.1Level: LLTClassification code 10020668Term: HyperlipoproteinemiaSystem Organ Class: 100000004861MedDRA version: 19.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2016-003373-18-NLIonis Pharmaceuticals, Inc.270